Yahoo Web Search

Search results

  1. May 6, 2021 · In the current report, Pfizer-BioNTech and Moderna vaccine products were equally represented, and approximately one half of the patients were aged ≥75 years, providing evidence of real-world effectiveness of both vaccines against an important measure of severe COVID-19 in older adults.

    • Mark W. Tenforde, Samantha M. Olson, Wesley H. Self, H. Keipp Talbot, Christopher J. Lindsell, Jay S...
    • 2021
  2. Nov 3, 2023 · In December 2020, the Pfizer-BioNTech COVID-19 vaccine two-dose series was found to be both safe and 91% to 95% effective in preventing COVID-19 infection in people age 18 and older. This data helped predict how well the vaccines would work for younger people.

  3. Jan 12, 2022 · Tenforde MW, Self WH, Naioti EA, et al. Sustained effectiveness of Pfizer-BioNTech and Moderna vaccines against COVID-19 associated hospitalizations among adults — United States, March–July 2021.

  4. Mar 11, 2021 · Vaccine effectiveness was at least 97% against symptomatic COVID-19 cases, hospitalizations, severe and critical hospitalizations, and deaths. Furthermore, the analysis found a vaccine effectiveness of 94% against asymptomatic SARS-CoV-2 infections. For all outcomes, vaccine effectiveness was measured from two weeks after the second dose.

  5. The Pfizer-BioNTech vaccine requires two injections, given 21 days apart, to prime the immune system well enough to fight off the coronavirus. But because the vaccine is so new, researchers don ...

  1. People also search for